Publication date: Aug 30, 2019
Artificial intelligence (AI) proves to have enormous potential in many areas of healthcare including research and chemical discoveries. Using large amounts of aggregated data, the AI can discover and learn further transforming these data into “usable” knowledge. Being well aware of this, the world’s leading pharmaceutical companies have already begun to use artificial intelligence to improve their research regarding new drugs. The goal is to exploit modern computational biology and machine learning systems to predict the molecular behaviour and the likelihood of getting a useful drug, thus saving time and money on unnecessary tests. Clinical studies, electronic medical records, high-resolution medical images, and genomic profiles can be used as resources to aid drug development. Pharmaceutical and medical researchers have extensive data sets that can be analyzed by strong AI systems. This review focused on how computational biology and artificial intelligence technologies can be implemented by integrating the knowledge of cancer drugs, drug resistance, next-generation sequencing, genetic variants, and structural biology in the cancer precision drug discovery.
Open Access PDF
Nagarajan, N., Yapp, E.K.Y., Le, N.Q.K., Kamaraj, B., Al-Subaie, A.M., and Yeh, H.Y. Application of Computational Biology and Artificial Intelligence Technologies in Cancer Precision Drug Discovery. 06554. 2019 Biomed Res Int (2019):
- A decision tree to improve identification of pathogenic mutations in clinical practice.
- Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers.
- Automating Automation – How close are we to Artificial Intelligence impact?